ZTALMY

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug ZTALMY contains one active pharmaceutical ingredient (API):

1 Ganaxolone UNII 98WI44OHIQ - GANAXOLONE

Ganaxolone is a methyl analogue of the endogenous neurosteroid allopregnanolone. Ganaxolone is a neuroactive steroid that positively and allosterically modulates gamma-aminobutyric acid type A (GABAA) receptors in the CNS by interacting with a recognition site that is distinct from other allosteric GABAA receptor modulators. Its anticonvulsant effects are thought to result from this modulation of GABAA receptor function providing constant, or tonic, modulation of GABA-mediated inhibitory neurotransmission. Read about Ganaxolone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZTALMY Oral suspension	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N03AX27		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3041200, 3041211
Country: FR	Base de données publique des médicaments	Identifier(s): 60294720
Country: IT	Agenzia del Farmaco	Identifier(s): 050778012, 050778024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097536, 1097537
Country: US	FDA, National Drug Code	Identifier(s): 81583-100